Navigation Links
Cipralex demonstrates superiority to duloxetine for acute treatment,of depression in new study

COPENHAGEN, June 4, 2007-A new study published today in the journal Current Medical Research and Opinion showed that Cipralex® (escitalopram) was superior to Cymbalta® (duloxetine) in the acute treatment of patients with major depressive disorder (MDD) and was at least as efficacious in long-term treatment. The study directly compared Cipralex® (an allosteric serotonin reuptake inhibitor - ASRI) to duloxetine (a serotonin and noradrenaline reuptake inhibitor - SNRI) and also demonstrated that Cipralex® was better tolerated, with fewer patients discontinuing treatment with Cipralex® due to adverse events compared to duloxetine.

Depression is a serious illness that results in significant disability and is associated with both increased morbidity and the risk of suicide. Affecting around 121 million people globally, the World Health Organization lists depression as the leading cause of disability worldwide.

"Cipralex® is an effective and well-tolerated drug for the treatment of depression and a wide range of anxiety disorders," said Senior Vice President Anders Gersel Pedersen, Head of Development at Lundbeck. "These new data provide further evidence of the strong efficacy and tolerability profile of Cipralex® compared to other antidepressants in the treatment of depression."

About the clinical study The study was designed to look at the efficacy and tolerability of Cipralex® compared to duloxetine in patients with moderate to severe MDD over 24 weeks, with a secondary endpoint at eight weeks (acute treatment).

The double-blind, fixed-dose, comparative study included 294 patients with MDD from 35 centres in nine countries. Patients were randomised to either Cipralex® (n=143) or duloxetine (n=151), at dosing regimens currently recommended in the package inserts in participating countries (Cipralex® 20mg, duloxetine 60mg).

Patients were evalu ated using the MADRS rating scale from baseline to week 24. Efficacy and tolerability were assessed at baseline and after 1, 2, 4, 8, 12, 16, 20 and 24 weeks; a safety follow-up visit was performed at 28 weeks. The 24-week study found that:

* Patients taking Cipralex® demonstrated significantly greater improvement in depression symptoms at week eight (acute treatment) than patients taking duloxetine. This superiority was evident after the first week of treatment and was maintained at all time points until week 16 (p<0.05)

* Cipralex® was at least as effective as duloxetine at 24 weeks of treatment, the primary endpoint of the study (p=0.055, Cipralex® being numerically better than duloxetine)

* Patients treated with Cipralex® showed significantly better functioning in their work, family and social life at week eight and week 24, compared to duloxetine

* Cipralex® was better tolerated than duloxetine. Significantly more duloxetine patients withdrew from the study due to adverse events than those treated with Cipralex® (17 percent versus nine percent respectively)

* A post-hoc analysis of the study revealed that 68.8 percent of patients had an early onset of response with Cipralex® compared to only 54.8 percent of duloxetine-treated patients

About depression Depression is a very common, debilitating illness affecting around 121 million people worldwide. The symptoms of depression can be chronic or recurrent, and impact patients both mentally and physically. Depression has a significant impact on patient quality of life and imposes a considerable burden on society, yet it is still underrecognised and undertreated with less than 25 percent of those affected having access to effective treatment.

Symptoms include feelings of hopelessness, sadness, guilt, loss of interest in activities, decreased energy, poor concentration, persistent physical symptoms such as headache and digestive disorders, and in more severe cases, suicidal thoughts and suicide attempts.

The content of this release will have no influence on the Lundbeck Group's financial result for 2007.

Lundbeck contacts

Investors: Media: Jacob Tolstrup Caroline Broge Investor Relations Manager, Media Relations Manager North America +45 36 43 26 38 +1 201 350 0187

________________________

Release no. 276 - 4 June 2007

About Lundbeck H. Lundbeck A/S is an international pharmaceutical company engaged in the research and development, production, marketing and sale of pharmaceuticals for the treatment of psychiatric and neurological disorders. In 2006, the company's revenue was DKK 9.2 billion (approximately EUR 1.2 billion or USD 1.6 billion). The number of employees is approx. 5300 globally. For more information, please visit www.lundbeck.com.


'"/>




Related medicine technology :

1. Newly Published Data Demonstrates Superiority of Cipralex Over Duloxetine for Acute Treatment of Depression
2. Amsterdam Molecular Therapeutics BV to present preclinical proof-of-concept data on its gene therapy AMT-020 to treat acute intermittent porphyria
3. Liraglutide provides significantly better glucose control than insulin glargine in phase 3 study
4. First single breast cancer study to show significant survival benefit for women switching from tamoxifen to Arimidex
5. Positive results from placebo-controlled phase IIa study in patients suffering from house dust mite allergy
6. 2007 ASCO Annual Meeting: Clinical Results on Phase IIb-study with AP 12009 in Anaplastic Astrocytoma selected for Poster Discussion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2017)... 15, 2017  Amy Baxter MD, chief executive officer ... noninvasive pain relief, was awarded a 2017 Top 40 ... was recognized at the MM&M Top 40 Healthcare Transformers ... on May 10, 2017. The dinner followed ... go "beyond the pill."  "Innovation goes beyond ...
(Date:5/12/2017)... May 12, 2017  The China and Canada ... that consumes less water, energy and detergent, and features a powerful ... LaughingU, a shoebox-sized washing machine that washes and sanitizes women,s panties ... ... is compact, and does not require an external water inlet. ...
(Date:5/10/2017)... May 10, 2017 Hologic, Inc. (Nasdaq: ... for the fiscal second quarter ended April 1, 2017 ... $1.84 increased 666.7% compared to the prior year period ... in a significant gain, while non-GAAP diluted EPS of ... or 3.8% in constant currency terms.  Excluding the effects ...
Breaking Medicine Technology:
(Date:5/22/2017)... ... , ... An inventor from Columbia, S.C., wants to offer people with manual ... in a firework accident, so she couldn’t grip a pen properly," he said. "This ... designed and created a prototype for the HELPEN HAND, a special pen that enables ...
(Date:5/22/2017)... Galena, Alaska (PRWEB) , ... May 22, 2017 , ... ... town near the Arctic Circle made big headlines when it was targeted to build ... Low-Cost Energy in Bush Alaska,” former city manager Marvin L. Yoder describes the journey ...
(Date:5/22/2017)... Francisco, CA (PRWEB) , ... May 22, 2017 ... ... will sponsor a program on Wellocity to empower WeightZone Factor members to ... their medications, and get an excellent health education, all on their mobile phones. ...
(Date:5/21/2017)... NY (PRWEB) , ... May 19, 2017 , ... Chris Cornell, 52, was found dead ... imagine why one of the most respected lead singers in the rock industry would take ... history of mental illness. FindaTopDoc investigates how mental illness played a role in the death ...
(Date:5/21/2017)... ... May 20, 2017 , ... ... between ABC Financial Services and financial systems. , Dozens of clubs ... files that are electronically processed through GetLinked into their club’s accounting system , ...
Breaking Medicine News(10 mins):